Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Net (2018 - 2025)

China SXT Pharmaceuticals (SXTC) has 8 years of Receivables - Net data on record, last reported at $1.3 million in Q1 2025.

  • For Q1 2025, Receivables - Net fell 1.02% year-over-year to $1.3 million; the TTM value through Mar 2025 reached $1.3 million, down 1.02%, while the annual FY2025 figure was $1.3 million, 1.02% down from the prior year.
  • Receivables - Net reached $1.3 million in Q1 2025 per SXTC's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $1.6 million in Q1 2021 and bottomed at $864709.0 in Q1 2022.
  • Average Receivables - Net over 5 years is $1.3 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Receivables - Net: tumbled 58.61% in 2021, then soared 55.49% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $1.6 million in 2021, then tumbled by 45.31% to $864709.0 in 2022, then soared by 55.49% to $1.3 million in 2023, then dropped by 2.22% to $1.3 million in 2024, then decreased by 1.02% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $1.3 million in Q1 2025, $1.3 million in Q1 2024, and $1.3 million in Q1 2023.